Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review
Open accessThe DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index; 111 of the 156 sources its claims cite were checked for support.
Abstract
Fungal infections, which commonly occur in immunocompromised patients, can cause high morbidity and mortality. Antifungal agents act by disrupting the cell membrane, inhibiting nucleic acid synthesis and function, or inhibiting β-1,3-glucan synthase.
Overview
CoChat Summary
TL;DR
This review summarizes antifungal agents that target mitochondrial components, especially electron transport chain complexes, DHODH, and Mir1, and catalogs their stages, spectra, MICs, in vivo efficacy, and selectivity. It concludes that mitochondria are promising but under-exploited antifungal targets, with only T-2307 and F90138 in clinical trials and most candidates still preclinical.
Key findings
- T-2307 (phase II) inhibits mitochondrial respiratory chain CIII and CIV; reported MICs are 0.00025–0.0039 μg/mL against Candida, 0.125–4 μg/mL against Aspergillus, and 0.0039–0.06 μg/mL against Cryptococcus, with >1,000-fold selectivity.
- F90138/olorofim (phase IIb) targets DHODH and is active against Aspergillus and Coccidioides with MIC ≤0.06 μg/mL; it shows >2,200-fold selectivity for A. fumigatus DHODH over the mammalian enzyme but is inactive against yeasts and Mucorales.
- Preclinical candidates include ilicicolin H (cytochrome bc1/CIII; MICs 0.01–5.0 μg/mL for Candida, 0.1–1.56 μg/mL for Cryptococcus, 0.08 μg/mL for Aspergillus), ML316 (Mir1; Candida MIC 0.008–1.156 μg/mL; reduced oropharyngeal candidiasis burden 100-fold alone and >1,000-fold with fluconazole), and Inz-5 (CIII; C. albicans MIC50 0.15 μg/mL; 27.8-fold selectivity).
- Natural products and antimicrobial peptides such as berberine, resveratrol, chiloscyphenol A, floricolin C, kalopanaxsaponin A, mefloquine derivatives, papaya seed extract, rosmarinic acid, P-113Du/P-113Tri, and ToAP2D affect mitochondrial function; many still lack specific targets, while P-113Du and P-113Tri inhibit NADH dehydrogenase/CI.
Methods
- Narrative review; no primary experimental design. It synthesizes published studies on mitochondrion-targeted antifungal drugs and mitochondrial targets.
- Data source: literature summarized in Table 1, covering agent, development stage, target, antifungal spectrum, in vitro MIC, in vivo efficacy, cytotoxicity IC50, and selectivity.
- Main analysis: qualitative synthesis of mechanisms, selectivity, and development stage; no systematic review or meta-analysis is described.
Limitations
- Stated: only a few drugs are under clinical trials; most agents target mitochondrial dysfunction broadly, and studies on other mitochondrial processes as targets are lacking. Exact targets of some compounds, such as 19ak and SM21, remain unclear, and some candidates have poor plasma or microsome stability.
- Stated: the close evolutionary relationship between fungi and humans makes selective mitochondrial targeting challenging; clinical candidates do not act on fungus-specific proteins but are highly selective toward fungal cells.
- Evident: as a narrative review, it lacks systematic search or inclusion criteria; many candidates are preclinical, and several Table 1 entries are “N/M,” limiting comparative efficacy and safety conclusions.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
97 Valid · 3 Not valid · 30 Not checked · 14 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Seven CTG clade-specific mitochondrial subunit proteins on the ETC are required for the expression of various ETC complexes and respiratory function and may be potential antifungal drug targets (12).”
§ Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review > ADVANTAGES OF MITOCHONDRIA AS TARGETS OF ANTIFUNGAL DRUGS
What the sources say
- Partly supportedcites [12] Sun N, Parrish RS, Calderone RA, Fonzi WA. 2019. Unique, diverged, and conserved mitochondrial functions influencing Candida albicans respiration. mBio 10. doi: 10.1128/mBio.00300-19. PMC6593398 31239372 sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) says seven CTG clade-specific proteins localized to mitochondria and were required for expression of various ETC complexes; the Discussion says they have essential roles in respiration. But the Discussion identifies only Nuo3 and Nuo4 as likely ETC subunits, leaves the others’ biochemical roles unresolved, and does not identify the seven proteins as potential antifungal drug targets. (LLM, conf=0.88)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“8.0% to 9.3% of Candida glabrata bloodstream isolates showed resistance to echinocandin”
§ Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review > INTRODUCTION
What the sources say
- Supportedcites [5] Perlin DS. 2014. Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management. Drugs 74: 1573– 1585. doi: 10.1007/s40265-014-0286-5. 25255923 PMC4201113 source
Section 3, ‘Epidemiology of Echinocandin Resistance,’ reports that the SENTRY surveillance program found 8.0–9.3% echinocandin resistance among 1,669 C. glabrata bloodstream isolates collected in 2006–2010. This directly supports the cited percentage and population. (LLM, conf=0.95)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Several studies have unraveled the mechanism of action of T-2307 and revealed that it is an inhibitor of mitochondrial respiratory chain CIII and CIV.”
§ Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review > MITOCHONDRIA-TARGETED ANTIFUNGALS WITH SPECIFIC TARGETS > Arylamidine T-2307.
What the sources say
- Partly supportedcites [35] Wiederhold NP. 2021. Review of T-2307, an investigational agent that causes collapse of fungal mitochondrial membrane potential. J Fungi (Basel) 7: 130. doi: 10.3390/jof7020130. 33670132 PMC7916847 sourceExperimental — accuracy not yet measured
The Structure and Mechanism of Action section reports that T-2307 inhibits the yeast mitochondrial respiratory chain, with further work suggesting that inhibition occurs mainly at complexes III and IV. The citing sentence presents that more tentative, yeast-specific finding as an unqualified established mechanism. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Although the antifungal drug candidates ilicicolin H, Inz-1 and Inz-5 act by inhibiting the highly conserved cytochrome bc1 reductase of CIII, the selectivity of ilicicolin H is approximately 50 times higher than that of Inz-1 or Inz-5.”
§ Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review > ANTIMICROBIAL PEPTIDES AFFECTING MITOCHONDRIAL FUNCTION > Conclusions and perspectives.
What the sources say
- Partly supportedcites [48] Vincent BM, Langlois J-B, Srinivas R, Lancaster AK, Scherz-Shouval R, Whitesell L, Tidor B, Buchwald SL, Lindquist S. 2016. A fungal-selective cytochrome bc1 inhibitor impairs virulence and prevents the evolution of drug resistance. Cell Chem Biol 23: 978– 991. doi: 10.1016/j.chembiol.2016.06.016. 27524297 PMC5159300 sourceExperimental — accuracy not yet measured
The Results section reports selectivity for Inz-1 and a selectivity index of 28 for Inz-5. In our copy, ilicicolin H appears only in a reference title; the paper does not give its selectivity or make the claimed approximately 50-fold comparison. (LLM, conf=0.83)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“SM21 significantly improved the murine survival rate in an invasive candidiasis model by 100% in 5 days.”
§ Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review > MITOCHONDRIA-RELATED ANTIFUNGAL HITS > SM21.
What the sources say
- Supportedcites [52] Wong SSW, Kao RYT, Yuen KY, Wang Y, Yang D, Samaranayake LP, Seneviratne CJ. 2014. In vitro and in vivo activity of a novel antifungal small molecule against Candida infections. PLoS One 9: e85836. doi: 10.1371/journal.pone.0085836. 24465737 PMC3899067 source
The Results section, “SM21 improves survival in a mouse model of systemic candidiasis” (Figure 12A; page not provided), reports 100% survival in SM21-treated mice versus 0% in untreated mice at day 5. This supports the claimed improvement in the murine systemic candidiasis model. (LLM, conf=0.91)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
64 more claims · 38 with their cited sources checked
Create a free account to see all 144 claims and to verify the 5 references still open.
- It may state two separate claims as one. 66
- Probably not a substantial claim. 12
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review > NATURAL ANTIFUNGAL HITS AFFECTING MITOCHONDRIAL FUNCTION
“RA showed potent anticandidal activity, with an MIC range of 0.1 to 0.2 mg/mL (76).”
§ Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review > ADVANTAGES OF MITOCHONDRIA AS TARGETS OF ANTIFUNGAL DRUGS
“| Rosmarinic acid | Preclinical | Mitochondrial function | Candida | 0.1–0.2 | N/M | 360.31 (HepG2) | 1,801.55–3,603.1 | 75, 76 |”
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review > MITOCHONDRIA-TARGETED ANTIFUNGALS WITH SPECIFIC TARGETS > Arylamidine T-2307.
“the MIC of T-2307 ranges from 0.00025 to 0.0039 μg/mL against Candida species”
§ Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review > ADVANTAGES OF MITOCHONDRIA AS TARGETS OF ANTIFUNGAL DRUGS
“| T-2307 | Phase II clinical trials | CIII, CIV | Candida | 0.00025–>4 | Murine models of invasive candidiasis, aspergillosis, and cryptococcosis | N/Mc | >1,000 | 28–31, 35, 39 |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review > ADVANTAGES OF MITOCHONDRIA AS TARGETS OF ANTIFUNGAL DRUGS
“Moreover, Nuo1 and Nuo2 are fungus-specific CI subunits, which may be more suitable for antifungal targets (8, 16).”
§ Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review > ANTIMICROBIAL PEPTIDES AFFECTING MITOCHONDRIAL FUNCTION > Conclusions and perspectives.
“(iii) broadly specific proteins in fungi, algae, plants but not in mammals (Nuo1)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review > MITOCHONDRIA-TARGETED ANTIFUNGALS WITH SPECIFIC TARGETS > Ilicicolin H.
“inhibition of Candida, Cryptococcus, and Aspergillus spp., with MICs ranging from 0.04 to 1.56 μg/mL (44).”
§ Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review > ADVANTAGES OF MITOCHONDRIA AS TARGETS OF ANTIFUNGAL DRUGS
“| Ilicicolin H | Preclinical | Cytochrome bc1 reductase (CIII) | Candida | 0.01–5.0 | Murine models of invasive candidiasis and cryptococcosis | N/M | >1,000 | 44, 46 |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review > MITOCHONDRIA-RELATED ANTIFUNGAL HITS > 19ak.
“19ak also has low cytotoxicity (IC50, 26.79 mg/mL in the HK2 cell line) and a high selectivity index (214.32)”
§ Recent Progress in Research on Mitochondrion-Targeted Antifungal Drugs: a Review > ADVANTAGES OF MITOCHONDRIA AS TARGETS OF ANTIFUNGAL DRUGS
“| 19ak | Preclinical | CI | Candida | 0.125–1 | G. mellonella model of C. albicans infection | 26.79 (HK2) | 214.32 (HK2) | 49 – 51 |”
Citations
Cites
Zielonka, J., Joseph, J., Sikora, A., Hardy, M., Ouari, O., Vasquez-Vivar, J., Cheng, G., Lopez, M., & Kalyanaraman, B. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00042 · Cited by 1,683 · cited 1×
“The mitochondrion is considered a therapeutic target for a variety of diseases (cancer, cardiovascular diseases, neurological diseases, and infections), not only because of its important functions in cell viability but also because of its mitochondrial targeting characteristics (22).”
BackgroundMitochondrial proteins: from biogenesis to functional networks
Pfanner, N., Warscheid, B., & Wiedemann, N. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0092-0 · Cited by 1,028 · cited 1×
“The realization of diverse mitochondrial functions depends on the action of functional proteins (10).”
BackgroundHealth benefits of resveratrol: Evidence from clinical studies
Singh, A. P., Singh, R., Verma, S. S., Rai, V., Kaschula, C. H., Maiti, P., & Gupta, S. C. (2019) · Medicinal Research Reviews · doi:10.1002/med.21565 · Cited by 523 · cited 1×
“Although clinical trials have proved the safety of resveratrol in the human body, further in vivo research on its use for the treatment of fungal infections is still needed (66).”
BackgroundAntibacterial and antifungal properties of resveratrol
Vestergaard, M., & Ingmer, H. (2019) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2019.02.015 · Cited by 482 · cited 1×
“300 m g/mL (60, 61).”
Mechanisms and regulation of protein synthesis in mitochondria
Kummer, E., & Ban, N. (2021) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00332-2 · Cited by 349 · cited 1×
“dria, most of which are encoded by the cell nucleus and highly conserved among species (9).”
BackgroundIsavuconazole: A New Broad-Spectrum Triazole Antifungal Agent
Miceli, M. H., & Kauffman, C. A. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ571 · Cited by 338 · cited 1×
“tions, adverse effects, and cross-resistance limit their clinical applicability (6).”
A Review of the Anti-Inflammatory Effects of Rosmarinic Acid on Inflammatory Diseases
Luo, C., Zou, L., Sun, H., Peng, J., Gao, C., Bao, L., Ji, R., Jin, Y., & Sun, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00153 · Cited by 336 · cited 1×
“for its therapeutic mechanism of action on diseases related to mitochondrial dysfunction (75).”
BackgroundF901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase
Oliver, J. D., Sibley, G. E. M., Beckmann, N., Dobb, K. S., Slater, M. J., McEntee, L., du Pré, S., Livermore, J., Bromley, M. J., Wiederhold, N. P., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608304113 · Cited by 289 · cited 1×
“F90138 targets DHODH, an essential mitochondrial enzyme that catalyzes the conversion of dihydroorotate to orotate in the de novo pyrimidine biosynthesis pathway (40).”
BackgroundZinovkin, R. A., & Zamyatnin, A. A. (2019) · Current Molecular Pharmacology · doi:10.2174/1874467212666181127151059 · Cited by 209 · cited 2×
“Several effective strategies for mitochondrial targeting have already been developed (23, 24).”
Hope on the Horizon: Novel Fungal Treatments in Development
Rauseo, A. M., Coler-Reilly, A., Larson, L., & Spec, A. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa016 · Cited by 199
Liu, D., Jin, F., Shu, G., Xu, X., Qi, J., Kang, X., Yu, H., Lu, K., Jiang, S., Han, F., et al. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2019.04.034 · Cited by 169 · cited 1×
“Moreover, targeting peptides such as Szeto-Schiller peptide and mitochondria-penetrating peptide facilitate peptide-tagged target compounds to localize within the mitochondria (26, 27).”
BackgroundEmerging Antifungal Targets and Strategies
Ivanov, M., Ćirić, A., & Stojković, D. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052756 · Cited by 160 · cited 1×
“It was synthesized based on ToAP2 and exhibited antifungal activity against Sporothrix globosa with good serum stability and low toxicity (81).”
da Silva, A. R., de Andrade Neto, J. B., da Silva, C. R., Campos, R. D. S., Costa Silva, R. A., Freitas, D. D., do Nascimento, F. B. S. A., de Andrade, L. N. D., Sampaio, L. S., Grangeiro, T. B., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01846-15 · Cited by 139 · cited 1×
“Berberine is a common isoquinoline alkaloid with extensive pharmacological activities, including anti-inflammatory, anticancer, and antimicrobial activities, and is effective for Candida infection treatment, especially for fluconazole-resistant Candida isolates (56, 57).”
BackgroundThe Future of Antifungal Drug Therapy: Novel Compounds and Targets
Mota Fernandes, C., Dasilva, D., Haranahalli, K., McCarthy, J. B., Mallamo, J., Ojima, I., & Del Poeta, M. (2021) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01719-20 · Cited by 124
du Pré, S., Beckmann, N., Almeida, M. C., Sibley, G. E. M., Law, D., Brand, A. C., Birch, M., Read, N. D., & Oliver, J. D. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00231-18 · Cited by 111
In Vitro and In Vivo Antifungal Activities of T-2307, a Novel Arylamidine
Mitsuyama, J., Nomura, N., Hashimoto, K., Yamada, E., Nishikawa, H., Kaeriyama, M., Kimura, A., Todo, Y., & Narita, H. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01159-07 · Cited by 111 · cited 2×
“In contrast, T-2307 has shown fungicidal activity against Aspergillus nidulans and Aspergillus niger in the MFC range of 0.0313 to 0.0625 m g/mL and fungistatic activity against other Aspergillus spp. (29).”
BackgroundInfluentialFungicidal Effect of Resveratrol on Human Infectious Fungi
Jung, H. J., Hwang, I. A., Sung, W. S., Kang, H., Kang, B. S., Seu, Y. B., & Lee, D. G. (2005) · Archives of Pharmacal Research · doi:10.1007/bf02977758 · Cited by 107
In Vitro and In Vivo Activity of a Novel Antifungal Small Molecule against Candida Infections
Wong, S. S. W., Kao, R. Y. T., Yuen, K. Y., Wang, Y., Yang, D., Samaranayake, L. P., & Seneviratne, C. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085836 · Cited by 107 · cited 1×
“A high-throughput screening of a library containing 50,240 small molecules showed that SM21 is a potent inhibitor of the yeast-hypha transition (52).”
BackgroundJanbon, G., Quintin, J., Lanternier, F., & d’Enfert, C. (2019) · Genes and Immunity · doi:10.1038/s41435-019-0071-2 · Cited by 102
Echinocandin Resistance, Susceptibility Testing and Prophylaxis: Implications for Patient Management
Perlin, D. S. (2014) · Drugs · doi:10.1007/s40265-014-0286-5 · Cited by 99 · cited 1×
“which has been a major obstacle for treatment (5).”
BackgroundT-2307 Causes Collapse of Mitochondrial Membrane Potential in Yeast
Shibata, T., Takahashi, T., Yamada, E., Kimura, A., Nishikawa, H., Hayakawa, H., Nomura, N., & Mitsuyama, J. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05954-11 · Cited by 99 · cited 1×
“T-2307 has high selectivity for fungal mitochondria over mammalian cells, which makes it a potent drug candidate for fungal infection (34, 39).”
BackgroundRosmarinic acid–Modes of antimicrobial and antibiofilm activities of a common plant polyphenol
Ivanov, M., Kostić, M., Stojković, D., & Soković, M. (2022) · South African Journal of Botany · doi:10.1016/j.sajb.2021.11.050 · Cited by 98 · cited 1×
“reduction of mitochondrial activity (76).”
Sun, N., Fonzi, W., Chen, H., She, X., Zhang, L., Zhang, L., & Calderone, R. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01520-12 · Cited by 94
In Vitro and In Vivo Antimalarial Activities of T-2307, a Novel Arylamidine
Kimura, A., Nishikawa, H., Nomura, N., Mitsuyama, J., Fukumoto, S., Inoue, N., & Kawazu, S.-I. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05856-11 · Cited by 93
Li, D., Chen, H., Florentino, A., Alex, D., Sikorski, P., Fonzi, W. A., & Calderone, R. (2011) · Eukaryotic Cell · doi:10.1128/ec.00303-10 · Cited by 91
Chang, W., Liu, J., Zhang, M., Shi, H., Zheng, S., Jin, X., Gao, Y., Wang, S., Ji, A., & Lou, H. (2018) · Nature Communications · doi:10.1038/s41467-018-07633-9 · Cited by 91 · cited 1×
“demonstrated that TPP1 confers protection to candidate compounds from being expelled by efflux pumps and helps the compounds to exert fungicidal effects by aiding them to localize within the mitochondrial matrix (25).”
BackgroundDevelopment and research progress of anti-drug resistant fungal drugs
Cui, X., Wang, L., Lü, Y., & Yue, C. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.08.004 · Cited by 85
Wiederhold, N. P., Najvar, L. K., Jaramillo, R., Olivo, M., Birch, M., Law, D., Rex, J. H., Catano, G., & Patterson, T. F. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00999-18 · Cited by 80
Heard, S. C., Wu, G., & Winter, J. M. (2021) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2021.02.001 · Cited by 78 · cited 1×
“A wide variety of antifungal drugs have been obtained by isolating them from natural products (amphotericin B, nystatin, natamycin, and pentamycin) or by modifying natural products (anidulafungin, caspofungin, and micafungin) (55).”
BackgroundYamashita, K., Miyazaki, T., Fukuda, Y., Mitsuyama, J., Saijo, T., Shimamura, S., Yamamoto, K., Imamura, Y., Izumikawa, K., Yanagihara, K., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00374-19 · Cited by 77 · cited 2×
“T-2307 has high selectivity for fungal mitochondria over mammalian cells, which makes it a potent drug candidate for fungal infection (34, 39).”
BackgroundMitochondrion-Targeting Peptides and Peptidomimetics: Recent Progress and Design Principles
Kim, S., Nam, H. Y., Lee, J., & Seo, J. (2020) · Biochemistry · doi:10.1021/acs.biochem.9b00857 · Cited by 75 · cited 1×
“Moreover, targeting peptides such as Szeto-Schiller peptide and mitochondria-penetrating peptide facilitate peptide-tagged target compounds to localize within the mitochondria (26, 27).”
BackgroundMitochondria targeted fluorogenic theranostic agents for cancer therapy
Singh, H., Sareen, D., George, J. M., Bhardwaj, V., Rha, H., Lee, S. J., Sharma, S., Sharma, A., & Kim, J. S. (2022) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.214283 · Cited by 72 · cited 3×
“Several effective strategies for mitochondrial targeting have already been developed (23, 24).”
BackgroundNovel Antifungal Mechanism of Resveratrol: Apoptosis Inducer in Candida albicans
Lee, J., & Lee, D. G. (2015) · Current Microbiology · doi:10.1007/s00284-014-0734-1 · Cited by 71 · cited 8×
“ToAP2D could trigger the apoptotic pathway in S. globosa and induce mitochondrial dysfunction, including a decrease in MMP and ROS accumulation.”
BackgroundInfluentialBerberine reverses multidrug resistance in Candida albicans by hijacking the drug efflux pump Mdr1p
Tong, Y., Zhang, J., Sun, N., Wang, X.-M., Wei, Q., Zhang, Y., Huang, R., Pu, Y., Dai, H., Ren, B., et al. (2021) · Science Bulletin · doi:10.1016/j.scib.2020.12.035 · Cited by 70
Exploiting mitochondria as targets for the development of new antifungals
Li, D., & Calderone, R. (2017) · Virulence · doi:10.1080/21505594.2016.1188235 · Cited by 67 · cited 7×
“Several studies have unraveled the mechanism of action of T-2307 and revealed that it is an inhibitor of mitochondrial respiratory chain CIII and CIV.”
BackgroundInfluentialAntifungal Spectrum, In Vivo Efficacy, and Structure–Activity Relationship of Ilicicolin H
Singh, S. B., Liu, W., Li, X., Chen, T., Shafiee, A., Card, D., Abruzzo, G., Flattery, A., Gill, C., Thompson, J. R., et al. (2012) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300173e · Cited by 63
In vitro Antifungal Effects of Berberine Against Candida spp. In Planktonic and Biofilm Conditions
Xie, Y., Liu, X., & Zhou, P. (2020) · Drug Design, Development and Therapy · doi:10.2147/dddt.s230857 · Cited by 63 · cited 1×
“Berberine is a common isoquinoline alkaloid with extensive pharmacological activities, including anti-inflammatory, anticancer, and antimicrobial activities, and is effective for Candida infection treatment, especially for fluconazole-resistant Candida isolates (56, 57).”
BackgroundDB75, a Novel Trypanocidal Agent, Disrupts Mitochondrial Function in Saccharomyces cerevisiae
Lanteri, C. A., Trumpower, B. L., Tidwell, R. R., & Meshnick, S. R. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.10.3968-3974.2004 · Cited by 59 · cited 1×
“As pentamidine and furamidine cause collapse of mitochondrial membrane potential (MMP) in yeast, T2307 is speculated to demonstrate the same effects (36).”
BackgroundVincent, B. M., Langlois, J.-B., Srinivas, R., Lancaster, A. K., Scherz-Shouval, R., Whitesell, L., Tidor, B., Buchwald, S. L., & Lindquist, S. (2016) · Cell Chemical Biology · doi:10.1016/j.chembiol.2016.06.016 · Cited by 58 · cited 2×
“Inz-1 is an indazole compound obtained during a phenotypic high-throughput screening with an aim to search for potent antifungal agents against azole-resistant strains (48).”
BackgroundSynthesis, cytotoxicity and antifungal activity of 5-nitro-thiophene-thiosemicarbazones derivatives
de Araújo Neto, L. N., do Carmo Alves de Lima, M., de Oliveira, J. F., de Souza, E. R., Buonafina, M. D. S., Vitor Anjos, M. N., Brayner, F. A., Alves, L. C., Neves, R. P., & Mendonça-Junior, F. J. B. (2017) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2017.05.005 · Cited by 57 · cited 1×
“Although the mechanism of action of 19ak has been related to the inhibition of CI and iron chelation, the exact target remains unclear (50, 51).”
BackgroundSeyedmousavi, S., Chang, Y. C., Law, D., Birch, M., Rex, J. H., & Kwon-Chung, K. J. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00129-19 · Cited by 56 · cited 1×
“In vivo experiments have shown that F90138 treatment improves survival and reduces fungal burden in murine models of neutropenia and chronic granulomatous disease with invasive aspergillosis (42).”
BackgroundBittner Fialová, S., Kello, M., Čoma, M., Slobodníková, L., Drobná, E., Holková, I., Garajová, M., Mrva, M., Zachar, V., & Lukáč, M. (2019) · Molecules · doi:10.3390/molecules24061078 · Cited by 53
She, X., Khamooshi, K., Gao, Y., Shen, Y., Lv, Y., Calderone, R., Fonzi, W., Liu, W., & Li, D. (2015) · Cellular Microbiology · doi:10.1111/cmi.12438 · Cited by 51 · cited 1×
“ciency will cause CI disassembly, reduced oxygen consumption, increased intracellular ROS, and decreased chronological aging in vitro and decreased virulence in a murine model (19).”
BackgroundNishikawa, H., Fukuda, Y., Mitsuyama, J., Tashiro, M., Tanaka, A., Takazono, T., Saijo, T., Yamamoto, K., Nakamura, S., Imamura, Y., et al. (2017) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx020 · Cited by 51 · cited 1×
“T-2307 has shown broad-spectrum antifungal activity against fungal pathogens, including Candida , Aspergillus , and Cryptococcus spp. (28 – 31).”
BackgroundUnique, Diverged, and Conserved Mitochondrial Functions Influencing Candida albicans Respiration
Sun, N., Parrish, R. S., Calderone, R. A., & Fonzi, W. A. (2019) · mBio · doi:10.1128/mbio.00300-19 · Cited by 51 · cited 2×
“CIII and CIV are involved in the regulation of antifungal susceptibility, as mutants of these two subunits show hypersusceptibility to fluconazole (12).”
BackgroundThe Novel Arylamidine T-2307 Demonstrates In Vitro and In Vivo Activity against Candida auris
Wiederhold, N. P., Najvar, L. K., Jaramillo, R., Olivo, M., Patterson, H., Connell, A., Fukuda, Y., Mitsuyama, J., Catano, G., & Patterson, T. F. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02198-19 · Cited by 50 · cited 1×
“T2307 has also demonstrated antifungal effects on Candida auris infection, which is refractory for its resistance to several antifungal agents (30).”
BackgroundInnate Inspiration: Antifungal Peptides and Other Immunotherapeutics From the Host Immune Response
Mercer, D. K., & O'Neil, D. A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02177 · Cited by 50 · cited 2×
“Histatin 5, a histatin family member, has signi fi cant antifungal potency against Candida spp., C. neoformans , and A. fumigatus (78, 79).”
BackgroundInhibiting mitochondrial phosphate transport as an unexploited antifungal strategy
McLellan, C. A., Vincent, B. M., Solis, N. V., Lancaster, A. K., Sullivan, L. B., Hartland, C. L., Youngsaye, W., Filler, S. G., Whitesell, L., & Lindquist, S. (2018) · Nature Chemical Biology · doi:10.1038/nchembio.2534 · Cited by 49 · cited 2×
“ML316 is a novel selective inhibitor of the fungal mitochondrial phosphate carrier Mir1, and it exhibits potent antifungal effects, especially on azole-resistant C. albicans (7).”
BackgroundInfluentialSusceptibility of Candida biofilms to histatin 5 and fluconazole
Konopka, K., Dorocka-Bobkowska, B., Gebremedhin, S., & Düzgüneş, N. (2010) · Antonie van Leeuwenhoek · doi:10.1007/s10482-010-9417-5 · Cited by 48
Wiederhold, N. P., Najvar, L. K., Fothergill, A. W., Bocanegra, R., Olivo, M., McCarthy, D. I., Fukuda, Y., Mitsuyama, J., & Patterson, T. F. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkv398 · Cited by 48
p-Terphenyl Derivatives from the Endolichenic Fungus Floricola striata
Li, W., Gao, W., Zhang, M., Li, Y.-L., Li, L., Li, X.-B., Chang, W.-Q., Zhao, Z.-T., & Lou, H.-X. (2016) · Journal of Natural Products · doi:10.1021/acs.jnatprod.6b00197 · Cited by 48 · cited 1×
“…a p -terphenyl derivative isolated from the fungus Floricola striata , exhibits antifungal activity against C. albicans , with an MIC 80 value of 8 m g/mL, and it induces mitochondrial dysfunction by causing ROS accumulation, which further contributes to cell nuclear dispersion and death (68, 69).”
BackgroundDegola, F., Morcia, C., Bisceglie, F., Mussi, F., Tumino, G., Ghizzoni, R., Pelosi, G., Terzi, V., Buschini, A., Restivo, F. M., et al. (2015) · International Journal of Food Microbiology · doi:10.1016/j.ijfoodmicro.2015.02.009 · Cited by 46 · cited 1×
“Although the mechanism of action of 19ak has been related to the inhibition of CI and iron chelation, the exact target remains unclear (50, 51).”
BackgroundUptake of T-2307, a novel arylamidine, in Candida albicans
Nishikawa, H., Yamada, E., Shibata, T., Uchihashi, S., Fan, H., Hayakawa, H., Nomura, N., & Mitsuyama, J. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq177 · Cited by 46 · cited 5×
“However, the required concentration of T2307 to induce the collapse of the fungal MMP is signi fi cantly higher than its MICs (37).”
BackgroundInfluentialMontoya, M. C., Beattie, S., Alden, K. M., & Krysan, D. J. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02331-19 · Cited by 42
He, X., Ma, Y., Yi, G., Wu, J., Zhou, L., & Guo, H. (2017) · Letters in Applied Microbiology · doi:10.1111/lam.12711 · Cited by 41
Zhang, T., & Chen, W. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18091858 · Cited by 37 · cited 1×
“The inhibitory mechanisms of PSE are attributed to mitochondrial dysfunction for ROS generation and MMP collapse (74).”
BackgroundWiederhold, N. P. (2021) · Journal of Fungi · doi:10.3390/jof7020130 · Cited by 37 · cited 2×
“T-2307 causes the disruption of MMP and mitochondrial dysfunction (35).”
BackgroundWiederhold, N. P., Najvar, L. K., Fothergill, A. W., Bocanegra, R., Olivo, M., McCarthy, D. I., Kirkpatrick, W. R., Fukuda, Y., Mitsuyama, J., & Patterson, T. F. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.04228-14 · Cited by 36
Li, Y., Shan, M., Zhu, Y., Yao, H., Li, H., Gu, B., & Zhu, Z. (2020) · PLOS ONE · doi:10.1371/journal.pone.0243066 · Cited by 35 · cited 1×
“albicansmembrane, causing intracellular trehalose to leak out and a decrease in membrane ergosterol contents (71).”
BackgroundNishikawa, H., Sakagami, T., Yamada, E., Fukuda, Y., Hayakawa, H., Nomura, N., Mitsuyama, J., Miyazaki, T., Mukae, H., & Kohno, S. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw095 · Cited by 34 · cited 1×
“albicans cells through an Agp2-regulated high-affinity spermine and spermidine carrier (38).”
BackgroundSingh, S. B., Liu, W., Li, X., Chen, T., Shafiee, A., Dreikorn, S., Hornak, V., Meinz, M., & Onishi, J. C. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.03.023 · Cited by 33 · cited 2×
“The plasma protein binding of 4,19-diacetate and 19-cyclopropyl acetate was reduced by approximately 20-fold (46).”
BackgroundLin, X., Yuan, S., Chen, S., Chen, B., Xu, H., Liu, L., Li, H., & Gao, Z. (2019) · Molecules · doi:10.3390/molecules24122267 · Cited by 31 · cited 1×
“Ilicicolin J is an analog of ilicicolin H produced by heterologous expression of ilicicolin H and displays similar antifungal activity as that of ilicicolin H (47).”
BackgroundDuan, X., Xie, Z., Ma, L., Jin, X., Zhang, M., Xu, Y., Liu, Y., Lou, H., & Chang, W. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.01951-21 · Cited by 31 · cited 1×
“As a thiosemicarbazone derivative, 19ak is a potent agent for fungal infection treatment, as it acts by inhibiting mitochondrial respiration by retarding mitochondrial respiratory chain CI activity (49).”
BackgroundThe synergistic antifungal activity of resveratrol with azoles against Candida albicans
Wang, J., Zhang, X., Gao, L., Wang, L., Song, F., Zhang, L., & Wan, Y. (2021) · Letters in Applied Microbiology · doi:10.1111/lam.13458 · Cited by 29
Self-citationResveratrol lacks antifungal activity against Candida albicans
Collado-González, M., Guirao-Abad, J. P., Sánchez-Fresneda, R., Belchí-Navarro, S., & Argüelles, J.-C. (2012) · World Journal of Microbiology and Biotechnology · doi:10.1007/s11274-012-1042-1 · Cited by 27 · cited 1×
“However, the mechanism by which resveratrol alone has signi fi cant antifungal activity against C. albicans remains unclear (62 – 64).”
BackgroundFunctional diversity of complex I subunits in Candida albicans mitochondria
Li, D., She, X., & Calderone, R. (2016) · Current Genetics · doi:10.1007/s00294-015-0518-6 · Cited by 27 · cited 1×
“gus-specific CI subunits, which may be more suitable for antifungal targets (8, 16).”
BackgroundA mitochondrial proteomics view of complex I deficiency in Candida albicans
She, X., Zhang, P., Gao, Y., Zhang, L., Wang, Q., Chen, H., Calderone, R., Liu, W., & Li, D. (2018) · Mitochondrion · doi:10.1016/j.mito.2017.08.003 · Cited by 26 · cited 1×
“, and it plays a major role in membrane transportation, intracellular ROS regulation, and trafficking between peroxisomes and mitochondria (17, 18).”
BackgroundNovel mitochondrial complex I-inhibiting peptides restrain NADH dehydrogenase activity
Xue, Y.-P., Kao, M.-C., & Lan, C.-Y. (2019) · Scientific Reports · doi:10.1038/s41598-019-50114-2 · Cited by 25 · cited 6×
“All these mitochondrial proteins in mitochondrial ETC are potential targets for antifungal agents in the future, since their de fi ciency will result in disastrous damage to cell vitality.”
BackgroundInfluentialZheng, S., Chang, W., Zhang, M., Shi, H., & Lou, H. (2018) · Scientific Reports · doi:10.1038/s41598-017-18717-9 · Cited by 23 · cited 3×
“It is effective against Candida species, with a MIC range of 8 to 32 m g/mL; an in vivo study veri fi ed the antifungal effects of CA in a Caenorhabditis elegans model (67).”
BackgroundChen, H., Calderone, R., Sun, N., Wang, Y., & Li, D. (2012) · Fungal Genetics and Biology · doi:10.1016/j.fgb.2012.09.007 · Cited by 21 · cited 1×
“, and it plays a major role in membrane transportation, intracellular ROS regulation, and trafficking between peroxisomes and mitochondria (17, 18).”
BackgroundZhang, M., Chang, W., Shi, H., Li, Y., Zheng, S., Li, W., & Lou, H. (2018) · FEMS Yeast Research · doi:10.1093/femsyr/foy002 · Cited by 20 · cited 1×
“…a p -terphenyl derivative isolated from the fungus Floricola striata , exhibits antifungal activity against C. albicans , with an MIC 80 value of 8 m g/mL, and it induces mitochondrial dysfunction by causing ROS accumulation, which further contributes to cell nuclear dispersion and death (68, 69).”
BackgroundMiyashiro, C. A., Bernegossi, J., Bonifácio, B. V., de Toledo, L. G., Ramos, M. A. S., Bauab, T. M., & CHORILLI, M. (2020) · Die Pharmazie · doi:10.31083/ph.2020.9165 · Cited by 19
Synergistic Antifungal Activity of Berberine Derivative B-7b and Fluconazole
Li, L. P., Liu, W., Liu, H., Zhu, F., Zhang, D. Z., Shen, H., Xu, Z., Qi, Y. P., Zhang, S. Q., Chen, S. M., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0126393 · Cited by 17 · cited 1×
“Berberine has shown a synergistic antifungal effect with azoles, especially with fluconazole (58).”
BackgroundNew Mitochondrial Targets in Fungal Pathogens
Murante, D., & Hogan, D. A. (2019) · mBio · doi:10.1128/mbio.02258-19 · Cited by 17 · cited 3×
“Several studies have unraveled the mechanism of action of T-2307 and revealed that it is an inhibitor of mitochondrial respiratory chain CIII and CIV.”
BackgroundUdawatte, N. S., Kang, S. W., Wang, Y., Arumugam, T. V., & Seneviratne, C. J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00511 · Cited by 17
Gerlach, E. S., Altamirano, S., Yoder, J. M., Luggya, T. S., Akampurira, A., Meya, D. B., Boulware, D. R., Rhein, J., & Nielsen, K. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.695240 · Cited by 17
Use of Haploid Model of Candida albicans to Uncover Mechanism of Action of a Novel Antifungal Agent
Truong, T., Suriyanarayanan, T., Zeng, G., Le, T. D., Liu, L., Li, J., Tong, C., Wang, Y., & Seneviratne, C. J. (2018) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2018.00164 · Cited by 16 · cited 1×
“SM21 has effects on the dysfunction of mitochondrial components, including collapsed MMPs, reduced ATP generation, increased ROS production, and decreased antioxidant potency (54).”
BackgroundLi, Y., Shan, M., Yan, M., Yao, H., Wang, Y., Gu, B., Zhu, Z., & Li, H. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.02844 · Cited by 16
The antifungal pipeline: the need is established. Are there new compounds?
Li, D., She, X., & Calderone, R. (2020) · FEMS Yeast Research · doi:10.1093/femsyr/foaa023 · Cited by 16
She, X., Zhang, L., Peng, J., Zhang, J., Li, H., Zhang, P., Calderone, R., Liu, W., & Li, D. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.559975 · Cited by 16 · cited 1×
“of C. albicans (20).”
Antifungal Activity of ToAP2D Peptide Against Sporothrix globosa
Yan, T., Li, F., Li, J., & Chen, F. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.761518 · Cited by 16 · cited 1×
“ToAP2D could inhibit the growth of S. globosa in vitro and induce its deformation and rupture (82).”
Background(2020) · PubMed · doi:10.1691/ph.2020.9165 · Cited by 15 · cited 1×
“A novel liquid crystal system has been developed to improve the antifungal effects of resveratrol by increasing its contact time with infected buccal sites (63).”
BackgroundThe Antimicrobial Peptides P-113Du and P-113Tri Function against Candida albicans
Lin, G.-Y., Chen, H.-F., Xue, Y.-P., Yeh, Y.-C., Chen, C.-L., Liu, M.-S., Cheng, W.-C., & Lan, C.-Y. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00699-16 · Cited by 14 · cited 2×
“Furthermore, a 12-amino-acid fragment of histatin 5, called P-113, was synthesized and proved to retain strong candidacidal activity without causing adverse effects in clinical trials (80).”
BackgroundJunker, B., Zhang, J., Mann, Z., Reddy, J., & Greasham, R. (2001) · Biotechnology Progress · doi:10.1021/bp0001718 · Cited by 9
Mitochondrial Toxicity of Organic Arsenicals
Liu, Y.-J., & Liu, Y. (2022) · Methods in Molecular Biology · doi:10.1007/978-1-0716-2309-1_11 · Cited by 3 · cited 1×
“CIII is a cytochrome bc1 complex that mediates the transfer of electrons from ubiquinol to cytochrome c (21).”
Background
Cited by
Next-generation antifungal drugs: Mechanisms, efficacy, and clinical prospects
Lu, X., Zhou, J., Ming, Y., Wang, Y., He, R., Li, Y., Feng, L., Zeng, B., Du, Y., & Wang, C. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.06.013 · Cited by 56
“Additionally, antifungal drugs targeting intracellular proteins hinder fungal proliferation by inhibiting nucleic acid synthesis, disrupting the electron transport chain, or impairing microtubule dynamics 10,11 (Fig.”
The progress and future of the treatment of Candida albicans infections based on nanotechnology
Gao, Y., Cao, Q., Xiao, Y., Wu, Y., Ding, L., Huang, H., Li, Y., Yang, J., & Meng, L. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02841-6 · Cited by 34
“Compared to the model yeast Saccharomyces cerevisiae , the mitochondria of fungal pathogens are different [89].”
ResultWeerasinghe, H., Stölting, H., Rose, A. J., & Traven, A. (2024) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00171-22 · Cited by 31
“For example, T-2307 which inhibits mitochondrial respiration at complexes III and IV in the respiratory chain (107) and F90138 which targets A. fumigatus pyrimidine biosynthe sis enzyme dihydroorotate dehydrogenase (DHODH) are in clinical trials, reviewed in reference (108).”
Deciphering the role of mitochondria in human fungal drug resistance
Ma, Y., Zhou, Y., Jia, T., Zhuang, Z., Xue, P., & Yang, L. (2025) · Mycology: An International Journal on Fungal Biology · doi:10.1080/21501203.2025.2473507 · Cited by 14
“Recent advancements in drug discovery have led to significant progress in the development of mitochon-drion-targeted antifungal agents, highlighting the potential of various novel compounds in combating fungal infections (Qin et al. 2023).”
Yang, Y., Zeng, Y., Liu, Z., & Huang, J. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1714998 · Cited by 16
Metadata
- Authors
- Qin, Y., Wang, J., Lv, Q., & Han, B.
- Affiliations
- Fudan University (CN)
- Second Military Medical University (CN)
- Corresponding author
- Lv, Quanzhen
- Han, Bing
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2023-06-15
- Volume
- 67
- Issue
- 6
- Pages
- e0000323-e0000323
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- PMC
- PMC10269089
- OpenAlex
- W4376873051
- Cited by
- 38
- References
- 84
- Citations by year
- 2026: 14 · 2025: 13 · 2024: 11
- FWCI
- 1.80
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (vor)
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Antimicrobial Agents and Chemotherapy (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- MOST | National Natural Science Foundation of China (82204468)
- Shanghai Minhang District Health Commission (2021MW01)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Agricultural and Biological Sciences › Plant Science › Fungal Plant Pathogen Control
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
- Keywords
- fungal infection, mitochondrial electron transport chain, mitochondrial respiration, reactive oxygen species, intracellular ATP, antifungal resistance, immunocompromised patients, lead compounds
- MeSH terms
- Antifungal Agents, Fungal Proteins, Humans, Mitochondria, Mycoses, Drug Delivery Systems
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.